A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial

Alistair S Hall, Beryl M Jackson, Amanda J Farrin, Maria Efthymiou, Julian H Barth, Joanne Copeland, Kristian M Bailey, Simon P R Romaine, Anthony J Balmforth, Terry McCormack, Andrew Whitehead, Marcus D Flather, Jane Nixon, SPACE ROCKET Trial Group

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


We sought to evaluate reports that rosuvastatin 10 mg is a more efficacious treatment of hyperlipidaemia than is simvastatin 40 mg, hoping to assess this issue in the previously unstudied context of acute myocardial infarction.
Original languageEnglish
Pages (from-to)712-21
Number of pages10
JournalEuropean Journal of Cardiovascular Prevention and Rehabilitation
Issue number6
Publication statusPublished - Dec 2009


  • Aged
  • Biological Markers
  • Cholesterol
  • Cholesterol, LDL
  • Female
  • Fluorobenzenes
  • Great Britain
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hyperlipidemias
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Odds Ratio
  • Practice Guidelines as Topic
  • Prospective Studies
  • Pyrimidines
  • Recurrence
  • Secondary Prevention
  • Simvastatin
  • Sulfonamides
  • Time Factors
  • Treatment Outcome

Cite this